NCT06503900View on ClinicalTrials.gov

Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

September 12, 2024

Primary Completion Date

August 20, 2025

Study Completion Date

October 21, 2025

Conditions
Birth OutcomesSafetyAdverse Event Following Immunization
Interventions
BIOLOGICAL

mRNA COVID-19 vaccine

ACIP-CDC recommended vaccine

BIOLOGICAL

IIV4 (quadrivalent inactivated influenza vaccine)

ACIP recommended vaccine

Trial Locations (6)

27101

Wake Forest University, Winston-Salem

27710

Duke University, Durham

30322

Emory University, Atlanta

30341

Centers for Disease Control and Prevention, Atlanta

45229

Elizabeth Schlaudecker, Cincinnati

02118

Boston Medical Center, Boston

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
lead

Duke University

OTHER

NCT06503900 - Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study | Biotech Hunter | Biotech Hunter